Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.

Biotechnology

Pharmaceutical

Calliditas Therapeutics

Frank Bringstrup

Teona Pipiya Johnson

Sandra Frithiof

Catherine Andrus

Fredrik Johansson

Karin Göhlin

Richard Philipson

Laura Roach

Sales and Marketing

Leadership Team

Clinical Operations and Medical Affairs

Finance and Accounting

Research and Development

Human Resources

Information Technology and Governance

Teams at Calliditas Therapeutics